Koh Youngil, Lee Hee Eun, Im Seock-Ah, Kim Se-Hyung, Kim Tae Min, Han Sae-Won, Oh Do-Youn, Kim Jee Hyun, Lee Se-Hoon, Kim Dong-Wan, Kim Tae-You, Kim Woo-Ho, Heo Dae Seog, Bang Yung-Jue
Department of Internal Medicine, Seoul National University Hospital, Korea.
Diagn Mol Pathol. 2011 Sep;20(3):143-7. doi: 10.1097/PDM.0b013e3182107ea0.
We intended to find predictive markers in advanced gastrointestinal stromal tumor patients treated with sunitinib. Korean patients who received sunitinib after imatinib failure for advanced gastrointestinal stromal tumor were studied. Genotyping for KIT and PDGFRA were performed. An immunohistochemical stain for PDGFR-α, PDGFR-β, and vascular endothelial growth factor (VEGF) was performed. A total of 22 patients were analyzed. Their median age was 55.1 years, and the male to female ratio was 12:10. The response rate of sunitinib was 30.4% and the median progression-free survival (PFS) was 10.1 months. In the sunitinib treatment, VEGF expression was related to a favorable response (P=0.002) and long PFS (P=0.020) in univariate analysis. CD34 (P=0.023) and PDGFR (P=0.022) expressions were also related to long sunitinib PFS in univariate analysis. However, the genotype did not affect either response rate or the PFS of sunitinib. In conclusion, expressions of VEGF, PDGFR, and CD34 may have predictive value in sunitinib treatments.
我们旨在寻找接受舒尼替尼治疗的晚期胃肠道间质瘤患者的预测性标志物。对伊马替尼治疗失败后接受舒尼替尼治疗的晚期胃肠道间质瘤韩国患者进行了研究。进行了KIT和PDGFRA基因分型。对PDGFR-α、PDGFR-β和血管内皮生长因子（VEGF）进行了免疫组织化学染色。共分析了22例患者。他们的中位年龄为55.1岁，男女比例为12:10。舒尼替尼的缓解率为30.4%，中位无进展生存期（PFS）为10.1个月。在舒尼替尼治疗中，单因素分析显示VEGF表达与良好的缓解（P=0.002）和较长的PFS（P=0.020）相关。CD34（P=0.023）和PDGFR（P=0.022）表达在单因素分析中也与舒尼替尼较长的PFS相关。然而，基因分型并未影响舒尼替尼的缓解率或PFS。总之，VEGF、PDGFR和CD34的表达可能在舒尼替尼治疗中具有预测价值。
